PURPOSE: A matched case-control study was performed to assess the relationship between metformin use and the degree of F-18 fluorodeoxyglucose (FDG) bowel activity in diabetic patients. MATERIALS AND METHODS: Seventy-seven diabetic patients referred to our department for a positron emission tomography/computed tomography study, including 45 on metformin, were compared with nondiabetic controls matched for sex, age, and body mass index. Positron emission tomography studies were obtained in a standard manner and reviewed in a blinded fashion. F-18 FDG uptake in the GI tract was evaluated quantitatively using maximal standardized uptake values and visually using a previously published semiquantitative scale. RESULTS: F-18 FDG uptake in small and large bowel was significantly increased in metformin patients compared with nondiabetic controls both visually and quantitatively (all P < 0.0001), as well as compared with nonmetformin patients with diabetes. Control sites (liver, fat, muscle) showed similar uptake. Multiple regression analysis confirmed that metformin was the variable most strongly associated with bowel uptake. CONCLUSION: Physiologic accumulation of F-18 FDG in bowel is increased in diabetic patients maintained on metformin.
PURPOSE: A matched case-control study was performed to assess the relationship between metformin use and the degree of F-18 fluorodeoxyglucose (FDG) bowel activity in diabeticpatients. MATERIALS AND METHODS: Seventy-seven diabeticpatients referred to our department for a positron emission tomography/computed tomography study, including 45 on metformin, were compared with nondiabetic controls matched for sex, age, and body mass index. Positron emission tomography studies were obtained in a standard manner and reviewed in a blinded fashion. F-18 FDG uptake in the GI tract was evaluated quantitatively using maximal standardized uptake values and visually using a previously published semiquantitative scale. RESULTS:F-18 FDG uptake in small and large bowel was significantly increased in metforminpatients compared with nondiabetic controls both visually and quantitatively (all P < 0.0001), as well as compared with nonmetformin patients with diabetes. Control sites (liver, fat, muscle) showed similar uptake. Multiple regression analysis confirmed that metformin was the variable most strongly associated with bowel uptake. CONCLUSION: Physiologic accumulation of F-18 FDG in bowel is increased in diabeticpatients maintained on metformin.
Authors: Mahsa Eskian; Abass Alavi; MirHojjat Khorasanizadeh; Benjamin L Viglianti; Hans Jacobsson; Tara D Barwick; Alipasha Meysamie; Sun K Yi; Shingo Iwano; Bohdan Bybel; Federico Caobelli; Filippo Lococo; Joaquim Gea; Antonio Sancho-Muñoz; Jukka Schildt; Ebru Tatcı; Constantin Lapa; Georgia Keramida; Michael Peters; Raef R Boktor; Joemon John; Alexander G Pitman; Tomasz Mazurek; Nima Rezaei Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-22 Impact factor: 9.236
Authors: Da Yeon Oh; Ji Won Kim; Seong-Joon Koh; Mingoo Kim; Ji Hoon Park; Su Yeon Cho; Byeong Gwan Kim; Kook Lae Lee; Jong Pil Im Journal: Intest Res Date: 2014-04-29